Jentadueto
NDC Package 54868-6461-0

11-digit billing NDC: 54868646100

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Jentadueto is contraindicated in patients with:Renal impairment (e.g., serum creatinine ≥1.5 mg/dL for men, ≥1.4 mg/dL for women, or abnormal creatinine clearance), which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia [see Warnings and Precautions (5.1, 5.3)]Acute or chronic metabolic acidosis, including diabetic ketoacidosis. Marketed by Physicians Total Care, Inc., this product is identified by NDC 54868-6461 and is authorized under FDA application NDA201281.

Identification & Billing

NDC Package Code
54868-6461-0
Package Description
60 TABLET, FILM COATED in 1 BOTTLE
Product Code
11-Digit Billing Format
54868646100
RxNorm Crosswalk
  • RxCUI: 1243020 - linagliptin 2.5 MG / metFORMIN HCl 1000 MG Oral Tablet
  • RxCUI: 1243020 - linagliptin 2.5 MG / metformin hydrochloride 1000 MG Oral Tablet
  • RxCUI: 1243026 - Jentadueto 2.5 MG / 1000 MG Oral Tablet
  • RxCUI: 1243026 - linagliptin 2.5 MG / metformin hydrochloride 1000 MG Oral Tablet [Jentadueto]
  • RxCUI: 1243026 - Jentadueto 2.5/1000 Oral Tablet

Clinical Specifications

Proprietary Name
Jentadueto
Dosage Form
-
Usage Information
JENTADUETO is contraindicated in patients with:Renal impairment (e.g., serum creatinine ≥1.5 mg/dL for men, ≥1.4 mg/dL for women, or abnormal creatinine clearance), which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia [see Warnings and Precautions (5.1, 5.3)]Acute or chronic metabolic acidosis, including diabetic ketoacidosis. Diabetic ketoacidosis should be treated with insulin [see Warnings and Precautions (5.1)]A history of hypersensitivity reaction to linagliptin, such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity [see Warnings and Precautions (5.6) and Adverse Reactions (6.1)]Hypersensitivity to metformin

Regulatory & Marketing

Labeler Name
Physicians Total Care, Inc.
FDA Application #
NDA201281
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
02-13-2012
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 54868-6461-0 identifies a specific commercial package of 60 tablet, film coated in 1 bottle of Jentadueto, labeled by Physicians Total Care, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Physicians Total Care, Inc. on February 13, 2012. The current certification is valid through December 31, 2017.

How is this Physicians Total Care, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 54868646100. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
54868-6461-0
11-Digit CMS (5-4-2)
54868-6461-00

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.